ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CSBR vs CRDF // FREE CASH FLOW YIELD

Champions Oncology Inc. (NASDAQ) VS. Cardiff Oncology Inc. (NASDAQ) • 15-METRIC TALLY: CSBR 6 — CRDF 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSBR VS. CRDF) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CSBR CRDF SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 48.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -26.90% -35.00% +8.10 CSBR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -7.52% — — TIE /fcf-yield <GO>
Operating Margin -1.90% -60.00% +58.10 CSBR /operating-margins <GO>
Net Profit Margin 0.00% -7.70% +7.70 CSBR /net-margins <GO>
Revenue Growth (YoY) 4.40% -13.20% +17.60 CSBR /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 CSBR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.7 38.9 +7.85 CSBR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $66.9M $70.9M -$4.0M CRDF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CSBR REV CRDF REV CSBR GROSS % CRDF GROSS % CSBR FCF CRDF FCF
FY 2025 $59.4M $593.0K 48.0% — -$5.0M -$38.0M
FY 2024 $56.9M $683.0K 50.1% — $7.0M -$37.8M
FY 2023 $50.2M $488.0K — — -$6.1M -$30.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSBR // BETA —
CRDF // BETA —